ANDA 70513, held by Watson Laboratories. Tolazamide.
As of Nov 21, 2026, ANDA 70513 (Tolazamide), held by Watson Laboratories, was first approved by FDA on Jan 9, 1986, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 9, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tolazamide100MG · tablet;oral | Tolazamide | Discontinued |
| Jun 3, 1997 | Supplement 10Manufacturing | Approved | None posted |
| Aug 7, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Jan 28, 1991 | Supplement 7Manufacturing | Approved | None posted |
| Jan 16, 1991 | Supplement 8Labeling | Approved | None posted |
| Jun 29, 1990 | Supplement 5Manufacturing | Approved | None posted |
| Jun 15, 1988 | Supplement 2Manufacturing | Approved | None posted |
| Jun 15, 1988 | Supplement 3Manufacturing | Approved | None posted |
| Jun 15, 1988 | Supplement 4Manufacturing | Approved | None posted |
| Jan 9, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters